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abstract
PURPOSE We conducted the phase III double-blind European Organisation for Research and Treatment of
Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected
high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median
follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P, .0001) compared with placebo. This led
to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and
Drug Administration. Here, we report an updated RFS analysis at the 3.05-year median follow-up.
PATIENTS AND METHODS A total of 1,019 patients with complete lymph node dissection of American Joint
Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis
. 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive
pembrolizumab at a flat dose of 200mg (n5 514) or placebo (n5 505) every 3 weeks for 1 year or until disease
recurrence or unacceptable toxicity. The two coprimary end points were RFS in the overall population and in
those with programmed death-ligand 1 (PD-L1)–positive tumors.
RESULTS Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged
RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively;
HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1–positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74).
The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8
staging, and BRAFmutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E/K
v wild type).
CONCLUSION In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained
and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent
across subgroups.
J Clin Oncol 38:3925-3936. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
In concordance with results obtained with immune
checkpoint inhibitors and BRAF plus MEK inhibitors
in advanced melanoma,1,2 adjuvant therapies with
ipilimumab,3-5 nivolumab,6 and pembrolizumab7 in
patients with melanoma at high risk for relapse re-
gardless of BRAFmutation status and with dabrafenib
plus trametinib8,9 in patients with BRAF mutation
demonstrated significant benefits that resulted in US
Food and Drug Administration (FDA) approvals for all
of these drugs. The ipilimumab,3-5 pembrolizumab,7
and dabrafenib plus trametinib8,9 trials were conducted
in patients with stage III disease with the restriction that
patients with American Joint Committee on Cancer
(AJCC) stage IIIA disease had to be at higher risk of
recurrence on the basis of tumor load in the sentinel
node (diameter . 1 mm, according to the Rotterdam
criteria).10-12 The CheckMate-238 (ClinicalTrials.gov
identifier: NCT02388906) nivolumab trial was con-
ducted in patients with stage IIIB-C and completely
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We conducted the phase III, randomized, double-blind
European Organisation for Research and Treatment of
Cancer (EORTC) 1325/KEYNOTE-054 trial (ClinicalTrials.
gov identifier: NCT02362594) to evaluate pembrolizumab
versus placebo in patients with resected high-risk stage III
melanoma. At the 1.25-year median follow-up, pem-
brolizumab adjuvant treatment prolonged RFS (hazard
ratio [HR], 0.57, P, .0001) compared with placebo.7 This
led to the approval of pembrolizumab adjuvant treatment
by the European Medicines Agency (EMA) and FDA.
We report an updated analysis at 3-year median follow-up
with regard to RFS outcome of the EORTC 1325/KEYNOTE-
054 trial to investigate whether the benefit is sustained and
whether patient characteristics, particularly programmed
cell death-ligand 1 (PD-L1) status; baseline stage according
to AJCC Cancer Staging Manual (seventh edition; AJCC-7),
and AJCC-8 classifications13,14; and BRAF-V600E/K mutation
status are of predictive importance for the treatment dif-
ference. Such analyses are important to confirm the initial
findings with a shorter follow-up7,15 and to compare them
with those provided by the COMBI-AD trial (ClinicalTrials.gov
identifier: NCT01682083) in BRAF-V600E/K–mutated mel-
anoma at 44 months median follow-up.9
PATIENTS AND METHODS
Patients
Patients (age $ 18 years) with histologically confirmed
cutaneous melanoma with metastasis to regional lymph
nodes were eligible to enter the study provided that a
complete regional lymphadenectomy could be performed
within 13 weeks before the start of treatment. Patients had
either stage IIIA melanoma (patients with N1a or N2a had to
have at least one micrometastasis measuring . 1 mm in
greatest diameter) or stage IIIB or IIIC disease with no in-
transit metastases according to the AJCC-7 classification.13
Exclusion criteria included Eastern Cooperative Oncology
Group performance status 2-4, presence of autoimmune
disease, uncontrolled infections, use of systemic cortico-
steroids, and prior systemic therapy for melanoma. A tumor
sample from melanoma-positive lymph nodes was required
to be sent for central pathology evaluation of PD-L1 ex-
pression. Membranous PD-L1 expression in tumor and
tumor-associated immune cells was assessed by an im-
munohistochemistry assay and scored on a scale of 0-5;
a score$ 2 (staining on. 1% of cells) was considered PD-
L1 positive.16
Study Design and Treatment
Registration was done centrally at the EORTC headquar-
ters. The randomization, using a minimization tech-
nique, was stratified by AJCC-7 staging (stage IIIA v
stage IIIB v stage IIIC with one to three positive nodes v
stage IIIC with more than three positive nodes) and
region. Only the local pharmacists were aware of trial
group assignments.
Patients were randomly assigned (1:1) to receive either an
intravenous infusion of pembrolizumab 200 mg or placebo
every 3 weeks for a total of 18 doses for approximately
1 year or until disease recurrence, unacceptable toxicity,
major protocol violation, or withdrawal of consent (Data
Supplement, online only). The primary end point was RFS,
as reported by the local investigators, in the overall pop-
ulation and in the subgroup of patients with PD-L1–positive
tumors.
Assessments
Computed tomography (CT) scans and magnetic reso-
nance imaging (MRI; full chest, abdomen, and pelvis CT
and/or MRI, neck CT and/or MRI for head and neck
CONTEXT
Key Objective
Does pembrolizumab treatment administration for 1 year lead to a sustained improvement of recurrence-free survival (RFS)
in resected high-risk stage III melanoma?
Knowledge Generated
Pembrolizumab as adjuvant therapy for patients with resected high-risk stage III melanoma provided a statistically sig-
nificant and clinically relevant 20% improvement of the RFS rate at 3 years compared with placebo and had a safety
profile consistent with the toxicity spectrum that already had been defined. Such RFS improvement was consistent across
subgroups, in particular according to programmed cell death-ligand 1 status, American Joint Committee on Cancer
Cancer Staging Manual (seventh edition; AJCC-7) and (eighth edition; AJCC-8), and BRAF mutation status.
Relevance
More than 1 year ago, pembrolizumab was already approved by the US Food and Drug Administration and European
Medicines Agency. These results confirm the clinical utility of pembrolizumab in the adjuvant setting in resected high-risk
stage III melanoma.We expect that these RFS improvements will also translate in terms of distant metastasis–free survival
and overall survival when long-term follow-up results are available.
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primaries, CT and/or MRI for other localizations [eg, brain,
deep soft tissue], only if clinically indicated) were per-
formed every 12 weeks for the first 2 years and every
6 months through year 5. Recurrence or metastatic lesions
had to be histologically confirmed whenever possible. The
first date when recurrence was observed was taken into
account.
RFS was defined as the time from random assignment until
the date of first recurrence (local, regional, or distant
metastasis) or death as a result of any cause. For patients
without any event, the follow-up was censored at the latest
disease evaluation performed according to the protocol.
Statistical Analysis
Details with regard to sample size computations, imple-
mentation of an interim analysis in an amended protocol,
and dissemination of the treatment outcome results were
provided in the original publication.7 The interim analysis,
which became the final one, was based on 351 RFS events
as reported on the clinical cutoff date of October 2, 2017.
The clinical cutoff date for the current analysis was Sep-
tember 30, 2019. This updated analysis, with a longer
follow-up, was performed to assess whether the initial
findings still hold true.
RFS distribution was estimated using the Kaplan-Meier
method, and the 95% CIs were estimated through the
Greenwood variance formula. For treatment comparison,
the log-rank test stratified by stage provided at randomi-
zation was used. The Cox model stratified by stage provided
at randomization was used to estimate the HRs and the CIs,
95% for the overall population and 99% for different
subgroups.
We investigated the possible predictive importance of
several factors (eg, AJCC-7 and AJCC-8 staging classifi-
cations, BRAF-V600E/K mutation status) on the treatment
differences with regard to RFS. Forest plots for the HRs
were produced, and results of the test of interaction be-
tween each factor and the treatment group in an un-
stratified Cox model were indicated. The treatment HRs for
each subgroup estimated using the model with the in-
teraction term were plotted along with their 99% CIs.
The cumulative incidence of the appearance of a distant
metastasis as the first RFS event was estimated by the
Aalen-Johansen method, and the treatment comparison
was performed using the Fine and Gray model stratified by
stage at random assignment. The primary analysis of RFS
included all the patients who underwent random assign-
ment, according to the intention-to-treat (ITT) principle.
Sensitivity analysis was based on the per-protocol treatment
(PPT) population: Eligible patients who started the treat-
ment were allocated by random assignment. The safety
profile was assessed in patients who started treatment
allocated by random assignment. All statistical analyses
were performed using SAS 9.4 software (SAS Institute,
Cary, NC).
Trial Oversight
The protocol was approved by the EORTC protocol review
committee and independent ethics committees. The trial
was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice. All patients provided
written informed consent.
RESULTS
Patients and Trial Regimen
From August 2015 through November 2016, 1,019 pa-
tients were randomly assigned at 123 centers in 23
countries: 514 patients were assigned to the pem-
brolizumab group and 505 to the placebo group. The
characteristics at baseline were similar between the two
groups (Data Supplement).
Eight patients did not start the treatment allocated by
random assignment (Fig 1). Of 509 patients who started
pembrolizumab, 72 (14.1%) discontinued treatment be-
cause of an adverse event (AE). Among 502 patients who
received placebo, 11 (2.2%) discontinued treatment be-
cause of an AE. A total of 109 (21.4%) patients in the
pembrolizumab group discontinued treatment because
of disease recurrence compared with 179 (35.7%) in
the placebo group. A total of 297 (58.3%) patients in the
pembrolizumab group and 300 (59.8%) patients in
the placebo group completed 1 year of treatment (Fig 1).
The median follow-up was 36.6 months (interquartile
range [IQR], 35.0-40.2 months) overall, 36.6 months
(IQR, 34.9-39.8 months) in the pembrolizumab group,
and 36.5 months (IQR, 35.0-40.5 months) in the
placebo group.
Updated RFS
In the ITT overall population, the 3-year RFS rate was
63.7% (95% CI, 59.2% to 67.7%) in the pembrolizumab
group and 44.1% (95%CI, 39.6% to 48.4%) in the placebo
group (Fig 2A). RFS remained significantly longer in the
pembrolizumab group than in the placebo group (HR
stratified by stage, 0.56; 95% CI, 0.47 to 0.68; P , .001).
During the additional follow-up period from the final
analysis,7 122 new RFS events were reported—55 in the
pembrolizumab group versus 67 in the placebo group. A
total of 473 patients had a recurrence or died—190
(37.0%) in the pembrolizumab group and 283 (56.0%) in
the placebo group (Data Supplement). Among them, 68
patients (13.2%) in the pembrolizumab group had
a locoregional recurrence only versus 92 (18.2%) in the
placebo group, and 117 (22.8%) patients developed dis-
tant metastases as their first recurrence (alone or combined
with locoregional recurrences in the pembrolizumab group)
versus 190 (37.6%) in the placebo group. The 3-year
cumulative incidence rate of distant metastasis being the
first site of recurrence was 22.3% (95% CI, 18.8% to
26.1%) in the pembrolizumab group and 37.3% (95% CI,
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33.0% to 41.6%) in the placebo group (HR, 0.55; 95% CI,
0.44 to 0.69; Data Supplement). There were four (0.8%)
deaths without recurrence (one as a result of myositis and
three unrelated to treatment) in the pembrolizumab group
and one (0.2%) in the placebo group. Sensitivity analysis
for RFS, on the basis of the PPT population, provided
similar results (HR, 0.56; 95% CI, 0.47 to 0.68).
Subgroup Analysis of RFS
The treatment difference with regard to RFS was consis-
tently observed across subgroups determined by all
baseline characteristics (Fig 3; Data Supplement).
RFS according to tumor PD-L1 expression. In the 853 pa-
tients with PD-L1–positive tumors, the 3-year RFS rate was
65.3% (95% CI, 60.5% to 69.7%) in the pembrolizumab
group and 46.4% (95%CI, 41.5% to 51.1%) in the placebo
group (HR stratified by stage, 0.57; 99% CI, 0.43 to 0.74;
P , .001; Fig 2B). Pembrolizumab was also consistently
effective in the 116 patients with PD-L1–negative tumors,
with the 3-year RFS rate being 56.9% (95% CI, 43.2% to
68.4%) in the pembrolizumab group and 33.3% (95% CI,
20.4% to 46.6%) in the placebo group (HR stratified by
stage, 0.45; 99%CI, 0.23 to 0.90; Fig 2C), and in those with
an undetermined tumor PD-L1 expression (Fig 3).
RFS according to AJCC-7 and AJCC-8. The benefit of
pembrolizumab was similar (P 5 .99) in the three AJCC-7
subgroups (Fig 3). The HRs stratified by stage as indicated
at random assignment were 0.50 (99% CI, 0.22 to 1.16),
0.56 (99% CI, 0.39 to 0.81), and 0.57 (99% CI, 0.40 to
0.81) in patients with stage IIIA, IIIB, and IIIC disease,
respectively (Fig 4). The 3-year RFS rates in the pem-
brolizumab and placebo groups were 81.2% and 66.3% in
the patients with stage IIIA, 65.7% and 47.0% in those with
stage IIIB, and 54.3% and 32.3% in those with stage IIIC
disease, respectively. The 99% CIs of these estimates are
shown in Figures 4A-4C.
The benefit of pembrolizumab was similar (P 5 .90) in the
four AJCC-8 subgroups (Fig 3). The HRs stratified by stage
provided at random assignment were 0.43 (99% CI, 0.13 to
Registered
(N = 1,464) 
Not randomly assigned
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1.43), 0.57 (99% CI, 0.36 to 0.90), 0.51 (99% CI, 0.37 to
0.70), and 0.68 (99% CI, 0.24 to 1.91) in patients with
stage IIIA, IIIB, IIIC, and IIID disease, respectively (Fig 5).
The 3-year RFS rates in the pembrolizumab and placebo
groups were 82.6% and 67.4% in the patients with stage
IIIA, 70.4% and 51.7% in those with stage IIIB, 59.6% and
35.2% in those with stage IIIC, and 45.0% and 22.2% in
those with stage IIID disease, respectively. The 99% CIs of
these estimates are shown in Figures 5A-5D.
RFS according to BRAF-V600E/K mutation status. The benefit
of pembrolizumab was consistent (P 5 .32) according to
BRAF status (Fig 3). In patients with BRAF-V600E/K –
mutated melanoma the HR stratified by stage was 0.51
(99% CI, 0.36 to 0.73) and the 3-year RFS rates were
62.0% (95% CI, 54.9% to 68.3%) and 37.1% (95% CI,
30.8% to 43.4%) in pembrolizumab and placebo groups,
respectively (Fig 6A). The approximate 1-, 2-, and 3-year
RFS rate improvements were 15% (72.2% v 57.6%),
360 298 259 226 215 126 28 0
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FIG 2. Recurrence-free survival (RFS) by treatment group. (A) In the overall population and according to programmed cell death-ligand 1 (PD-
L1) tumor status. (B) PD-L1 positive. (C) PD-L1 negative. EV/No., events/number of patients; HR, hazard ratio.
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25% (65.6% v 40.2%), and 25% (62.0% v 37.1%), re-
spectively. In patients withBRAFwild-typemelanoma the HR
stratified by stage was 0.66 (99% CI, 0.46 to 0.95) and the
estimated 3-year RFS rates in the pembrolizumab and pla-
cebo groups were 61.8% (95% CI, 55.1% to 67.8%) and
46.5% (95% CI, 39.6% to 53.2%), respectively (Fig 6B).
RFS according to other variables. The pembrolizumab
benefit was also similar in patients with microscopic and
macroscopic nodal involvement (test for interaction, P 5
.80) and in patients with and without ulcerated melanomas
(test for interaction, P 5 .38). Age, sex, and baseline body
mass index did not significantly influence the treatment
difference (Data Supplement).
Safety
At the time of the previous analysis, there were only 25
patients still receiving protocol treatment. Therefore, the
incidence of the AEs already reported in the previous
publication7 remained almost unchanged in the current
one. For instance, the treatment-related AEs of any grade
occurred in 398 (78.8%) of 509 patients (two additional
patients) in the pembrolizumab group and in 333 (66.3%)
of 502 patients (one additional patient) in the placebo
group. Treatment-related grade 3-5 AEs were observed
in 74 (14.5%) patients in the pembrolizumab group and
17 (3.4%) in the placebo group. There was one
pembrolizumab-related death as a result of myositis.
Compared with the previous report, immune-related AEs
(irAEs) of any grade occurred in two additional patients (ie,
in 192 patients; 37.7%) in the pembrolizumab group and
remained unchanged (9.0%) in the placebo group (Data
Supplement). As in the previous report, an increased in-
cidence of endocrine disorders was observed in the
pembrolizumab group compared with the placebo group
(23.4% v 5.0%); the most common endocrine disorders
were hypothyroidism (14.5% v 2.6%) and hyperthyroidism
(10.0% v 1.0%), and all were grade 1 or 2. The incidence of
sarcoidosis was low (1.2% v 0%), and all occurrences
were grade 1-2. The incidence of grade 3-4 irAEs remained
low (7.7% v 0.6%), including colitis (2.2% v 0.2%),
hypophysitis/hypopituitarism (0.6% v 0%), and type 1 di-
abetes mellitus (1.0% v 0%).
Events/No. of Patients
Pembrolizumab      Placebo HR CI
HR (CI)
(pembrolizumab:placebo) Interaction Test
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FIG 3. Forest plot of recurrence-free survival. AJCC, American Joint Committee on Cancer (seventh edition; AJCC-7; AJCC (eighth edition; AJCC-8), HR,
hazard ratio; PD-L1, programmed cell death-ligand 1; WT, wild type.
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DISCUSSION
The analysis at 3-year median follow-up of the EORTC
1325/KEYNOTE-054 trial comparing adjuvant therapy with
pembrolizumab with placebo in patients with resected
high-risk stage III melanoma demonstrates a sustained RFS
benefit. The updated HR estimate was 0.56, which is in line
with the previous estimate of 0.57 as assessed at the 1.25-
year median follow-up.7 With regard to safety and irAEs,
there were only a small number of additional cases com-
pared with the initial report in 2018.7 Therefore, we did not
re-analyze the positive association between irAEs and
outcome in pembrolizumab-treated patients.17
The absolute difference in RFS rates between the pem-
brolizumab group and the placebo group increased from
approximately 15% at 1 year to approximately 20% at 2 and
3 years. The benefit is consistent across all subgroups, in
particular according to PD-L1 status, AJCC-7 and -8
staging, and BRAF-V600E/K status as illustrated in the forest
plot (Fig 3). Predictive importance of ulceration status was
weak; the HR observed in patients with ulcerated
C
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FIG 4. Recurrence-free survival by treatment group according to the American Joint Committee on Cancer Cancer Staging Manual (seventh edition;
AJCC-7). (A) Stage IIIA. (B) Stage IIIB. (C) Stage IIIC. EV/No., events/number of patients; HR, hazard ratio.
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melanoma (0.54) was similar to the one in those with
nonulcerated melanoma (0.64). This contrasts with adju-
vant therapy with interferons (IFNs), where IFN sensitivity is
probably limited to ulcerated melanoma as observed in
retrospective studies.18-20 This was recently substantiated
by the results of the randomized adjuvant PEG-IFN EORTC
18081 trial in ulcerated stage II melanoma.21 With regard to
subgroup staging, it is interesting to observe that the es-
timated HR observed in the AJCC-7 stage IIIA subgroup
(0.50) was lower than in the stage IIIB or IIIC subgroups and
that among the four AJCC-8 subgroups, the lowest HR was
reported in the best prognostic AJCC-8 IIIA subgroup
(0.43). This observation of a clear benefit is important
because the indication of adjuvant therapy with anti–
programmed death 1 in these best prognostic AJCC sub-
groups is debated because of the risk of chronic irAEs.22
Of note, in our EORTC 1325/KEYNOTE-054 trial, the es-
timated improvement of RFS as a result of pembrolizumab
was larger in patients with BRAF-V600E/K mutant mela-
noma (HR, 0.51) than in BRAF wild-type melanoma (HR,
0.66), with an increased difference in 3-year RFS rate of
approximately 25% (62.0% v 37.1%) versus 15% (61.8% v
46.5%), respectively, versus placebo. It also indicates
a lack of prognostic importance of BRAF-V600 mutation
18 8 6 5 4 4 3 0
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FIG 5. Recurrence-free survival by treatment group according to American Joint Committee on Cancer Cancer Staging Manual (eighth edition; AJCC-8).
(A) Stage IIIA. (B) Stage IIIB. (C) Stage IIIC. (D) Stage IIID. EV/No., events/number of patients; HR, hazard ratio.
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status in the pembrolizumab group. In the advanced
melanoma setting, Larkin et al23 also showed that the
nivolumab group had a 5-year overall survival (OS) rate of
46% and 43% in patients with BRAF-V600 mutant and
wild-type melanoma, respectively, whereas in the nivolu-
mab plus ipilimumab group, it was 60% and 48%, re-
spectively. Of note, in patients with BRAF-V600 melanoma
recruited in the COMBI-v trial (ClinicalTrials.gov identifier:
NCT01597908), dabrafenib and trametinib combination
yielded a lower 5-year OS rate (34%).24 In addition, in
patients with BRAF-V600 mutation in the pembrolizumab
group of our EORTC 1325/KEYNOTE-054 trial, the 3-year
RFS rate of 62% was practically identical to the 59% ob-
served in the adjuvant dabrafenib plus trametinib combi-
nation arm of the COMBI-AD trial,8 whereas the 3-year RFS
rates were practically identical in the respective placebo
groups as well (37% v 40%). However, in each trial, the
absolute RFS rate improvement changed over time: In the
COMBI-AD trial,8 the estimated RFS benefit of the BRAF
and MEK inhibitor combination versus placebo was larger
than in our trial at 1 year (32% v 15%) but was approxi-
mately the same at 2 years (23% v 25%) and inferior at
3 years (19% v 25%). This retrospective, indirect com-
parison would suggest a crossing of the RFS curve of
dabrafenib plus trametinib combination with the one of
pembrolizumab at approximately 30 months from the start
of treatment, which would be similar to the crossing of the
progression-free survival and OS curves at approximately
16 months in advanced melanoma in pooled analyses.2,25
214 148 123 103 95 93 52 8 0
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Long-term RFS results are required to ascertain these
preliminary findings.
Whether the association of RFS benefit and OS benefit in
adjuvant trials in melanoma as established with IFNs and
ipilimumab26 will be upheld in the adjuvant trials with the
more active drugs nivolumab, pembrolizumab, and the
combination of dabrafenib and trametinib seems likely but
has not been formally demonstrated at this point in time
because of a lack of mature OS follow-up and a sufficient
number of events. The EORTC 1325/KEYNOTE-054 trial is
the only trial in which patients from the placebo arm could
cross over at the time of recurrence and receive experi-
mental treatment as part of the study protocol and, thus, will
play an important role in addressing this question. Cur-
rently, CheckMate-915 is assessing the value of adjuvant
combination therapy with nivolumab and ipilimumab
versus nivolumab in resected stage IIIB/CIV melanoma. A
press release communicated that at interim analysis, the
primary end point of RFS in the PD-L1–negative patient
population was not met.27 In resected stage IV melanoma,
the combination nivolumab plus ipilimumab therapy
seemed superior to nivolumab monotherapy in a random-
ized phase II trial, and both therapies were better than
placebo.28 Moreover, the current developments with neo-
adjuvant immunotherapy create new opportunities in a
constantly changing landscape of (neo)adjuvant therapy in
melanoma.29-34
In conclusion, pembrolizumab adjuvant therapy in resec-
ted high-risk stage III melanoma provided at the 3-year
median follow-up a sustained and clinically meaningful
improvement in RFS. This finding was consistent across
subgroups.
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CS Utrecht, the Netherlands; e-mail: alexander.eggermont@
prinsesmaximacentrum.nl.
EQUAL CONTRIBUTION
S.S. and C.R. contributed equally to this article.
PRIOR PRESENTATION
Presented at the American Society of Clinical Oncology Annual Meeting,
May 29-31, 2020.
SUPPORT
Supported by Merck & Co, Kenilworth, NJ.
CLINICAL TRIAL INFORMATION
NCT02362594 (MK-3475-054/1325-MG/KEYNOTE-054)
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
Disclosures provided by the authors are available with this article at DOI
https://doi.org/10.1200/JCO.20.02110.
AUTHOR CONTRIBUTIONS
Conception and design: Alexander M. M. Eggermont, Georgina V. Long,
Dirk Schadendorf, Alexander C. J. van Akkooi, Clemens Krepler, Sandrine
Marreaud, Stefan Suciu, Caroline Robert
Provision of study material or patients: Alexander M. M. Eggermont,
Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria G. Atkinson,
Shahneen Sandhu, James Larkin, Dirk Schadendorf, Anna Maria Di
Giacomo, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Caroline Robert
Collection and assembly of data: Alexander M. M. Eggermont, Christian U.
Blank, Mario Mandala, Georgina V. Long, Victoria G. Atkinson, Stéphane
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